WAVE LIFE SCIENCES LTD. Proceeds from Issuance or Sale of Equity
WAVE LIFE SCIENCES LTD. (WVE) reported Proceeds from Issuance or Sale of Equity of $323.20 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2018-05-09
- WAVE LIFE SCIENCES LTD. proceeds from issuance or sale of equity for the quarter ending 2018-03-31 was $323.20M.
- WAVE LIFE SCIENCES LTD. proceeds from issuance or sale of equity for fiscal 2017 was $323.20M.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|
| 2018-03-31 | $323.20M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $323.20M 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |